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Background: Hypospadias is a common male birth defect that has shown widespread variation in 
reported prevalence estimates. Many countries have reported increasing trends over recent 
decades.  
 
Objective: To analyze the prevalence and trends of hypospadias for 27 international programs 
over a 31-year period.  
 
Design, Setting, and Participants: The study population included live births, stillbirths, and 
elective terminations of pregnancy diagnosed with hypospadias during 1980-2010 from 27 
surveillance programs around the world.   
 
Outcome Measurements and Statistical Analysis: We used joinpoint regression to analyze 
changes over time by international total hypospadias prevalence across programs, prevalence for 
each specific program, and prevalence across different degrees of severity of hypospadias.  
 
Results and Limitations: The international total prevalence of hypospadias for all years was 20.9 
(95% CI 19.2-22.6) per 10,000 births. The prevalence for each program ranged from 2.1 to 39.1 
per 10,000 births.  The international total prevalence increased 1.6 times during the study period, 
by 0.25 cases per 10,000 births per year (p<0.05).  When analyzed separately, there were 
increasing trends for first-, second-, and third-degree hypospadias during the early 1990s to mid-
2000s.  The majority of programs (61.9%) had a significantly increasing trend during many of 





Conclusion: Although there have been changes in clinical practice and registry ascertainment 
over time in some countries, the consistency in the observed increasing trends across many 
programs and by degrees of severity suggest that the total prevalence of hypospadias may be 
increasing in many countries.  This observation is contrary to some previous reports suggesting 
that the total prevalence of hypospadias was no longer increasing in recent decades.   
 
Patient summary: We report on hypospadias prevalence and trends among 27 birth defects 
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Hypospadias, which is caused by incomplete development of the urethra, is one of the 
most common congenital anomalies in male infants, with an estimated prevalence of 64.7 cases 
per 10,000 male live births in the United States (1). Hypospadias can have different degrees of 
clinical severity, as defined by the location of the urethral opening (2). Estimates of the 
prevalence of hypospadias vary across and within different geographical settings globally. The 
extent to which artefactual differences (e.g., differences in clinical practice, registry 
ascertainment, or case definitions) contribute to the observed prevalence differences is unknown.  
Moreover, there have been reports of increases in the prevalence of hypospadias in many 
countries, especially in the last decades of the 20th century (2-9).  However, a number of 
countries have also reported that the prevalence has not increased in recent decades (3, 7, 9-17). 
To better understand prevalence trends in recent years across the world, we evaluated 
hypospadias data in 27 birth defect surveillance programs participating in the International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). 
 
MATERIALS AND METHODS 
Data Collection 
The ICBDSR is a World Health Organization-affiliated network of birth defects 
surveillance programs.  The general methods of the ICBDSR are described elsewhere (18).  Each 
of 27 surveillance programs identified hypospadias cases under their established protocol for 





We calculated an international total prevalence of hypospadias per 10,000 births, defined 
as the total number of cases - live births, stillbirths, and elective terminations of pregnancy for 
fetal anomaly (ETOPFAs) - across all 27 programs divided by the total number of births (live 
births and stillbirths, regardless of sex) during the full study period (1980-2010). (We reported 
the total prevalence per male and female births for comparability with international prevalence 
reports of other birth defects).  Because some programs did not have data between 1980 and 
1999, we also calculated the international total prevalence of hypospadias per 10,000 births for a 
more recent period (2000-2010). Lastly, we calculated the total prevalence of hypospadias for 
each individual program during 1980-2010 and 2000-2010. The approximate 95% confidence 
interval (CI) was also calculated for all prevalence estimates. In addition, we determined the 
quartile (1, 2, 3, or 4) in which each program’s total prevalence was located (e.g., programs in 
quartile 1 had a total prevalence within the lowest 25% of all the programs).   
To visualize the data over time and to assess temporal changes in trends, we conducted 
analyses using joinpoint regression. Joinpoint regression is helpful for identifying linear trends in 
total prevalence over time that are restricted to sub-periods, rather than testing for linear trends 
only across the entire time period (19). This approach agnostically identifies joinpoints that parse 
the data into periods of varying sizes, based on the presence of similar linear trends within each 
period (19).  
We conducted joinpoint regression for the total analytic group (all 27 programs) during 
the full study period. These analyses were repeated among a subset of 19 programs with three 
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characteristics (hereafter referred to as the “main sub-group”): (1) population-based 
ascertainment, (2) ascertainment of cases ≥1 year of age, and (3) ascertainment of cases from 
multiple sources. This sub-analysis was repeated again, only including 8 programs from the main 
sub-group with at least 30 years of data available.  For comparison, we plotted the total 
prevalence of these 8 programs over time on the same figure.  
We also conducted analyses separately for first-, second-, and third-degree hypospadias, 
including only the 12 programs for which the degree of severity was specified for ≥80% of cases.  
These analyses were repeated among 7 programs that were also in the main sub-group. 
To better understand similarities and differences across programs, analyses were also 
performed during the full study period for each separate program. (Programs with < 11 years of 
data or with intermediate years of missing data were not included in this analysis, in order to 
meet the software’s minimal requirements (19)). 
All statistical tests were two-sided and we interpreted statistical significance based on a 
p-value < 0.05. Joinpoint regression analyses were performed using Joinpoint Trend Analysis 




The characteristics of each program are summarized in Table 1. The majority of 
programs used population-based case identification (21 programs, 77.8%), registered cases up to   
12 months of age or beyond (22 programs, 81.5%), and received notification of cases from 
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multiple sources (19 programs, 70.4%). There were only 12 programs (44.4%) that specified the 
degree of severity of hypospadias in ≥80% of cases. 
 
International Prevalence of Hypospadias 
For all programs combined, there were 36,127,500 births and 74,814 cases with 
hypospadias.  The international total prevalence of hypospadias was 20.9 (95% CI: 19.2 -22.6) 
per 10,000 births among 27 programs of the ICBDSR during 1980-2010. For 2000–2010 
specifically, the international total prevalence was 23.8 (95% CI: 22.1 - 25.5) per 10,000 births. 
Program-specific prevalences for 1980-2010 and 2000-2010 were tabulated (Table 2) and also 
presented in a histogram (Figure 1). Arkansas, USA had the highest total prevalence (39.1 cases 
per 10,000 births, 95% CI: 36.7 - 41.4), while Argentina had the lowest total prevalence (2.1 
cases per 10,000 births, 95% CI: 1.1 - 4.8). Programs in Latin American countries (i.e., 
Argentina, Chile, Colombia, Mexico, and Costa Rica) had relatively lower total prevalence 
estimates than programs in other regions (Figure 1).  The total prevalence in Europe was highly 
variable, ranging from 10.6 (France) to 37.4 (Lombardia, Italy) cases per 10,000 births.  Only 4 
(Atlanta, Georgia, USA; Mexico; Spain; Slovak Republic) out of 27 programs had a lower total 
prevalence in the recent period (2000-2010) than the whole period (1980-2010) (Figure 1). 
The changes in the international total prevalence of hypospadias were visualized using 
joinpoint regression (Supplemental Figure 1), with joinpoints identified at 1996 and 1999.  Since 
1999, the total prevalence increased significantly by 0.25 cases per year (p=0.001). This analysis 
was repeated among the main sub-group (Figure 2a). For these programs, there was an increasing 
trend during the entire period 1980-2010, and this increase was statistically significant (p<0.001) 
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from 1980-1996 (0.19 cases per year) and 1999-2010 (0.34 cases per year). The analysis was 
repeated using data from the 8 programs with at least 30 years of data (Figure 2b). Among these 
programs, there was a 1.6 times increase in the total prevalence of hypospadias during the entire 
study period (from 1980-2010) by an average of 0.34 cases per year (p<0.001).  Among these 
programs (Figure 2c) France had a relatively lower total prevalence during the entire period. 
 
Prevalence of Hypospadias by Degree of Severity 
Figures 3a, 3b, and 3c show the results from joinpoint regression analyses for first-, 
second-, and third-degree hypospadias.  These analyses were restricted to programs with the 
degree of severity of hypospadias specified in ≥80% of cases (12 programs). Across all three 
degrees of severity, increasing trends were observed from the mid-1990s to the mid-2000s 
(Figure 3a, 3b, 3c). Similar trends were observed after repeating these analyses among 7 
programs that were also in the main sub-group (Supplemental Figure 2a, 2b, 2c).  Among these, 
62.2% of cases had first-degree hypospadias, 20.1% had second-degree hypospadias, 4.5% had 
third-degree hypospadias, and 13.2% had an unspecified degree of severity (data not shown). 
 
Program-Specific Prevalence of Hypospadias 
Supplemental Figure 3 illustrates the results from the joinpoint regression for each 
program with at least 11 years of data (the software’s minimal requirements). Five of the 27 
programs were excluded from these analyses because they had less than 11 years of data 
(Argentina; Colombia; Chile; Canada [National]; Iran). Because the software required complete 
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data for each year analyzed, New Zealand was also excluded due to missing data for some years. 
Table 3 summarizes the trends from these analyses. Different trend patterns were observed 
across programs, including patterns of total prevalence increases during much or all of the study 
period for a number of programs.  In fact, significant increases in the total prevalence of 
hypospadias were observed for 45.0% of the years of observation, whereas significant decreases 
in the total prevalence were observed for only 10.4% of the years of observation.  
 
DISCUSSION 
Among 27 programs participating in the ICBDSR, the total prevalence of hypospadias 
was 20.9 per 10,000 births during 1980-2010, though it varied greatly by geographical region. 
The international total prevalence of hypospadias increased during the entire study period, with 
significant increases from 2000 to 2010.  When we restricted to programs among the main sub-
group, the rates of increase were similar, though the time trend was significant over more years.  
The increasing trends were also consistent for most of the study period across all degrees of 
hypospadias clinical severity. 
Our international total prevalence estimates of hypospadias were similar to those from 
previous studies, with many previous reported estimates from individual ICBDSR programs, 
including the United States (5), Australia (2),  Germany (21), Northern Netherlands (21), 
Hungary (21), Malta (21), Spain (21) and Tuscany (21). For Latin American countries, our 
results were consistent with previous estimates from Argentina (22) and Mexico (23). In fact, all 
Latin American programs had a relatively low prevalence that fell within the lowest quartile of 
all participating programs. As the magnitude of the difference was quite large and consistent 
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across programs in Latin American countries, it is possible that the difference between Latin 
American countries and other countries may reflect true prevalence differences, perhaps related 
to differences in both genetic and non-genetic hypospadias risk factors.  
As previously reported, programs in the United States and northern Europe had higher 
prevalence estimates (23).There have been reports of increases in the prevalence of hypospadias 
in many countries, particularly during the late 1960s until around the early 1990s in the U.S. and 
in Europe (reviewed in (24)). Our results for 1980 to the early 1990s seem consistent with these 
reported increases. 
However, this increase was reported to stabilize or even decrease in more recent years in 
many, though not all, studies (3, 7, 21), whereas we detected an increase throughout this time. 
For example, separate reports from Washington State, USA (1987-2002 births) (17), New York 
State, USA (1983-1995 births) (13), Scotland (1988-1997 births) (11), Italy (2001-2004 births) 
(14), Finland (1970-1994 births) (12), and Europe (1980-1999 births from the EUROCAT 
Network) (7) did not indicate increases in the prevalence in more recent years.  Further, 
individual reports from Spain (1996-2002 births) (16), Northern England (1993-2000 births) 
(10), and Japan (1985-1997 births) (15), suggested that the prevalence may have been decreasing 
in recent years.  As expected, among these individual countries represented in our study (i.e., 
Finland, Italy, Spain, and other European regions), much of the corresponding data within these 
same time windows appeared similar in our data (i.e., not increasing).  However, our results 
among all programs indicated an increase in the total prevalence during recent years.  This 
difference was probably related to inclusion of a very large number of programs throughout a 
long (and in many instances, more recent) analysis period (1980-2010), as well as our use of 
joinpoint regression.  However, it is noteworthy that these increases were not observed during 
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the entire period for each program, and it is important to remember that our findings were most 
influenced by the programs with larger sample sizes. 
Although our study likely reflects a better estimate of global trends than smaller studies, 
it is likely that some of the observed prevalence increases in our study were artefactual, and 
reflect changes over time in how cases with hypospadias were identified and documented at the 
medical facility and/or were ascertained by the surveillance system (e.g., under-ascertainment in 
earlier years).  While quality metrics for systematic assessment of birth defect surveillance have 
been recently proposed (25), many programs have not yet reported on these metrics (26, 27).  
Some ICBDSR systems implemented systematic surveillance changes during the study period 
(Supplemental Table 1), including a stronger focus on ascertaining less severe hypospadias cases 
in more recent years (21) and improvements in data collection over time.   
Nevertheless, we still observed increasing prevalence time trends among the main sub-
group, which represented 47.0% of total births across all ICBDSR programs.  The data from 
these programs may have been less subject to bias compared to that from other sites, and these 
trends among this sub-group were similar to the trends observed in the full analytic group.  This 
consistency suggests that much of the increasing trends in the prevalence of hypospadias may 
represent a true (non-artefactual) increase.  However, consistent trends were not seen across 
every program. 
It has been proposed that the observed prevalence increase might reflect increases in 
exposure to hypospadias risk factors over time (9).  However, given the broad range of 
potentially relevant environmental and occupational exposures that could be responsible for the 
observed increase, as well as issues related to exposure dosage, timing, and other factors, it has 
been challenging to identify the main culprits.  It is also possible that changes over time in the 
13 
 
distribution of other parental factors associated with hypospadias risk (e.g., parity, body mass 
index, maternal age, fertility treatments) may have influenced the prevalence over time, but data 
were not available to assess this possibility in our analyses (24).  Further study of potential 
hypospadias risk factors, including genetic factors, endocrine disruptors, and other maternal and 
paternal exposures and characteristics may shed light on this possibility. 
This study had some known limitations. First, it lacked uniformity in data collection 
across programs, which may have led to heterogeneity among cases across programs.  Initiatives 
related to standardizing these methodologies across programs would be helpful to future work.  
Second, as individual-level data were not available, we could not adjust for differences in the 
distributions of hypospadias risk factors across countries, and this unmeasured confounding may 
have also partially accounted for the differences in hypospadias prevalence across programs. 
Third, the joinpoint regression modeled the data based on an assumption of linear trends across 
sub-periods, although it did not account for completely non-linear (e.g., exponential) trends. 
Nevertheless, this statistical approach did have more flexibility than a traditional assessment of a 
continuous prevalence estimate under the assumption of a linear change over an entire study 
period, which would not have been able to agnostically identify changes limited to study sub-
periods.  We also did not have data related to co-occurring congenital malformations (~88.5% of 
hypospadias is expected to be isolated in European countries (21)) or on hypospadias treatment; 
while we had data on hypospadias severity for some Programs, these data were not available for 
the majority of Programs.  
Despite these limitations, this study has several important strengths. We analyzed data 
from surveillance programs across the world, which represents one of the largest case samples 
among published studies.  Further, our data allowed us to look at trends over a thirty-one year 
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period. We also investigated the trends by differing degrees of severity and considered 
differences in characteristics of surveillance programs.  
 
CONCLUSION 
Our results suggest that the international total prevalence of hypospadias increased during 
1980-2010, and that these trends were probably not entirely artefactual. Considering these trends, 
it seems clear that further surveillance around hypospadias is critical. 
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Table 1   Summary of program characteristics, International Clearinghouse for Birth Defects Surveillance and Research 
Program Delivery years Total 
births 
Ascertain-













≥80% of cases  
Argentina
c
 2009-2010 42,136 No No No No 
Australia
d
 1980-2010 792,512 Yes Yes Yes Yes 
Canada (National)
e
 2005-2010 1,416,099 No Yes No No 
Alberta, Canada
f
 1980-2010 1,309,669 Yes Yes Yes No 
Chile-Maule
g
 2002-2010 119,900 No No No Yes 
Colombia 2001-2010 174,425 Yes No No Yes 
Costa Rica
h
 1987-2010 1,842,791 Yes
a
 Yes No No 
Czech Republic 1980-2010 3,597,530 Yes Yes Yes Yes 
Finland 1993-2010 1,068,457 Yes Yes Yes Yes 
France
i
 1980-2010 2,819,326 Yes Yes Yes No 
Germany
j
 1987-2010 336,716 Yes Yes Yes No 
Hungary 1980-2010 3,507,915 Yes Yes Yes No 
Iran
k
 2005-2010 130,724 Yes No Yes - 
b
 
Lombardia, Italy 1999-2010 179,484 Yes Yes Yes No 
Tuscany, Italy
l
 1992-2010 519,749 Yes Yes Yes No 
Malta
m
 1993-2010 77,261 Yes Yes Yes Yes 
Mexico
n
 1980-2010 1,093,745 No No No Yes 
New Zealand 1980-1993 1996-2010 1,638,216 Yes Yes Yes - 
b
 
Northern Netherlands 1981-2010 496,810 Yes Yes Yes Yes 
Slovak Republic 1995-2010 902,372 Yes Yes No Yes 
Spain
o
 1980-2010 2,648,286 No No No Yes 
Sweden 1980-2010 3,166,009 Yes Yes Yes No 
Arkansas, USA
p
 1993-2010 684,001 Yes Yes Yes Yes 
Atlanta, Georgia, USA
q
 1980-2010 1,299,822 Yes Yes Yes No 





 1999-2010 615,886 Yes Yes Yes Yes 
Wales
s
 1998-2010 430,710 Yes Yes Yes No 
a. For births during 2009 and later only 
b. No information on degree of severity 
c. National Network of Congenital Anomalies of Argentina (RENAC) 
d. Western Australian Register of Developmental Anomalies  
e. Canadian Congenital Anomalies Surveillance System  
f. Alberta Congenital Anomalies Surveillance System 
g. Registro de malformaciones congénitas del Servicio de Salud Maule (RRMC-SSM)  
h. Centro de Registro de Enfermedades Congénitas  
i. Registre des Malformations en Rhône-Alpes (REMERA)  
j. Saxony-Anhalt 
k. Tabriz Registry of Congenital Anomalies 
l. Tuscan Registry of congenital defects (RTDC)  
m. Malta Congenital Anomalies Register  
n. Registration and Epidemiologic Surveillance of External Congenital Malformations (RYVEMCE)  
o. Spanish Collaborative Study of Congenital Malformations (ECEMC)  
p. Arkansas Reproductive Health Monitoring System  
q. Metropolitan Atlanta Congenital Defects Program  
r. Utah Birth Defect Network 






Table 2  Total prevalence of hypospadias by program and time period, International Clearinghouse for Birth Defects Surveillance and 
Research 
   1980-2010 2000-2010 















Lower Upper Lower Upper 
Argentina  2009-2010 2.14 1.11 4.83 Q1 2.14 1.11 4.83 Q1 
Australia  1980-2010 33.68 31.58 35.34 Q4 36.21 34.26 38.32 Q4 
Canada (National) 2005-2010 24.45 23.57 25.31 Q3 24.45 23.57 25.31 Q3 
Alberta, Canada 1980-2010 21.13 19.77 22.31 Q3 21.51 19.84 22.94 Q2 
Chile-Maule 2002-2010 8.26 6.62 9.85 Q1 8.26 6.62 9.85 Q1 
Colombia 2001-2010 4.70 4.24 9.17 Q1 4.70 4.24 9.17 Q1 
Costa Rica 1987-2010 4.77 4.24 5.42 Q1 6.17 5.62 6.74 Q1 
Czech Republic 1980-2010 25.64 24.31 27.72 Q3 31.86 30.29 32.70 Q4 
Finland 1993-2010 15.54 14.64 16.37 Q2 15.97 14.74 17.11 Q2 
France 1980-2010 10.60 9.56 11.54 Q1 12.55 11.67 13.49 Q1 
Germany 1987-2010 18.21 16.47 20.61 Q2 19.32 17.09 21.65 Q2 
Hungary 1980-2010 22.30 21.17 23.92 Q3 25.78 23.28 28.35 Q3 
Iran 2005-2010 13.69 8.70 18.41 Q2 13.69 8.70 18.41 Q2 
Lombardia, Italy 1999-2010 37.38 33.42 40.92 Q4 38.11 34.17 41.70 Q4 
Tuscany, Italy 1992-2010 19.22 17.15 21.16 Q2 20.17 18.07 22.34 Q2 
Malta 1993-2010 29.64 22.46 38.88 Q4 36.45 26.22 47.28 Q4 
Mexico 1980-2010 3.17 2.67 3.40 Q1 2.75 2.04 3.53 Q1 
New Zealand 
1980-1993 1996-
2010 19.61 16.56 22.21 Q2 27.02 24.65 29.70 Q3 
Northern Netherlands 1981-2010 15.06 12.80 17.05 Q2 20.04 17.39 22.98 Q2 
Slovak Republic 1995-2010 21.98 20.30 23.81 Q3 21.35 19.09 23.93 Q2 
Spain 1980-2010 14.75 14.12 16.34 Q2 12.11 11.47 12.73 Q1 
Sweden 1980-2010 20.01 18.52 21.48 Q3 24.97 23.39 26.26 Q3 
Arkansas, USA 1993-2010 39.11 36.67 41.43 Q4 40.13 36.67 43.50 Q4 
18 
 
Atlanta, Georgia, USA 1980-2010 31.28 29.66 32.70 Q4 30.21 27.99 32.61 Q3 
Texas, USA 1996-2010 28.14 26.36 29.01 Q3 28.57 27.32 29.75 Q3 
Utah, USA 1999-2010 30.59 28.03 32.84 Q4 31.05 28.52 33.34 Q3 
Wales  1998-2010 31.65 30.57 32.80 Q4 32.15 31.25 33.13 Q4 
Total - 20.91 19.19 22.63 - 23.78 22.06 25.50 - 
a



































































































































































                              
Alberta, Canada  
         
       
              
Costa Rica \\\              
                        
Czech Republic 
                               
Finland                           
                  
France 
                               
German               
                        
Hungary 
                               
Lombardia, Italy                                       
            
Tuscany, Italy                         
                   
Malta                           
                  
Mexico 
                               
Northern Netherlands   
                              
Slovak Republic                               
                
Spain 
                               
Sweden 
                               
Atlanta, Georgia, USA 
        
 
                      
Arkansas, USA                           
                  
Texas, USA                                 
               
Utah, USA                                       
            
Wales                                
Key:                                
Years with a significantly increasing trend in total prevalence of hypospadias (p<0.05)                       
Years with a significantly decreasing trend (p<0.05)                       
Years with no significant trend (p≥0.0.5)                       
Years with no observations                       
A
Joinpoint regression was not performed for programs with <11 years of data (Argentina, Colombia, Chile, Canada [National], Iran) or any 




Supplemental Table 1.  Examples of reported systematic changes during 1980-2010 among International 
Clearinghouse for Birth Defects Surveillance and Research programs 
Program Location Systematic change 
Alberta, Canada During the 1990s, case ascertainment dropped during a period of financial uncertainty. 
Costa Rica The age of ascertainment changed from ~3 days to 1 year in 2008.  
Costa Rica New training activities were implemented in the mid and late 2000’s. 
Czech Republic Supplemental case ascertainment with additional newborn report records began in 2000.  
Czech Republic There were suspected changes in the awareness of hypospadias reporting requirements among 
neonatologists during the study period. 
France Data collection reportedly improved over time, as the number of data sources increased and other 
improvements in data quality were implemented. 
Hungary Reporting of documented birth defects became legally regulated and mandated in 1997, which 
resulted in higher numbers of most birth defects identified by early 2000.   
Hungary New procedures based on territorial representation were established in 2000, under which a 
different public health professional conducted the quality control of their respective county’s data.   
Many European 
programs 
EUROCAT registry guidelines changed in 2005 to include isolated first degree hypospadias, 
which was previously excluded.   
Many European 
programs 
ICD classification and codes changed from ICD-9 752.6 to ICD-10 Q54.0-54.9 in many European 
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Figure 1. Total prevalence of hypospadias (per 10,000) for International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) 








A) B)  
C)  
(A) Among 19 programs with 1) population-based ascertainment, 2) age of ascertainment ≥1 year, and 3) ascertainment from multiple sources.  (B) Among 8 programs with 1) 
population-based ascertainment, 2) age of ascertainment ≥1 year, 3) ascertainment from multiple sources, and 4) at least 30 years of data.  (C) Results by program, among 8 
programs with 1) population-based ascertainment, 2) age of ascertainment ≥1 year, 3) ascertainment from multiple sources, and 4) at least 30 years data.   
a
 Stars indicate joinpoints with statistically significant (p<0.05) trends. 
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Figure 3. Trends in the international total prevalence of hypospadias for 12 ICBDSR programs 
by clinical degree of severity, 1980-2010.
a,b
   
A)  B)  
C)  
A) First-degree hypospadias, B) second-degree hypospadias, and C) third-degree hypospadias  
a
 Stars indicate joinpoints with statistically significant (p<0.05) trends. 
b




Supplemental Figure 1. Trends in the international total prevalence of hypospadias for 27 
ICBDSR programs using joinpoint regression, 1980-2010.
a
   
 
a





Supplemental Figure 2. Trends in the international total prevalence of hypospadias by clinical 




   
 
A) B) C)  
A) First-degree hypospadias, B) second-degree hypospadias, and C) third-degree hypospadias  
a
 Programs with 1) the clinical degree of severity specified in ≥80% of cases, 2) population-based 
ascertainment, 3) age of ascertainment ≥1 year, and 4) ascertainment from multiple sources. 
b






















 Stars indicate joinpoints with statistically significant (p<0.05) trends. 
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b Joinpoint regression was not performed for programs with <11 years of data (Argentina, 
Colombia, Chile, Canada [National], Iran) or any years of missing data during the period 




Appendix A. Details of case surveillance and selection methods 
The International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) 
was created for the purpose of collecting and sharing data across individual birth defects 
surveillance programs worldwide. When new research projects are initiated by the ICBDSR or 
proposed by its members, a specific study protocol is approved and each program is invited to 
participate by providing existing data for that specific analysis, if not available from regular 
monitoring of birth defects. We obtained aggregate-level data on hypospadias from 27 birth 
defect surveillance programs in the ICBDSR. Since each program had data for a potentially 
different study period, we chose the study period to be births from 1980 to 2010, years for which 
the majority of programs had more complete data.  Surveillance methods and case definitions 
also vary between programs (18, 28). For example, for some programs, case identification is 
based on review of records by program staff for all births and terminations of pregnancy at all 
hospitals and delivery centers in the program’s region, whereas surveillance for other programs 
relies on clinician reporting of cases to the program. 
Programs identified cases based on infants with a recorded hypospadias diagnosis using 
the WHO International Classification of Diseases, ICD-9 (752.6) or ICD-10 (Q54) codes, in 
addition to reviewing the original birth defect descriptions.  A British Pediatric Association 
(BPA) code extension for the ICD-9 code was used to differentiate hypospadias (752.60) from 
epispadias (752.61) and congenital chordee alone (752.62).  The Royal College of Paediatrics 
and Child Health adaptation was used to identify the respective subtypes for ICD-10 codes.  
Thus, all systems could distinguish between hypospadias and epispadias or congenital chordee 
alone, which were not included in the study.   
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Cases among live births and stillbirths were included by all programs. Elective 
terminations of pregnancy for fetal anomaly (ETOPFA) were included by programs where 
terminations were permitted, except the hospital-based Spanish program. (This should not have 
strongly impacted the results since the prenatal diagnosis of hypospadias is very rare, and ~90% 
of the cases are isolated.)  For each program, data were available for the total number of cases 
with hypospadias (live births, stillbirths, and ETOPFA) during each year of surveillance and the 
total number of births (live births and still births) in the same surveillance region during each 
respective year.  
When available, we also received data on the number of cases with hypospadias by the 
degree of severity (first-degree, second-degree, third-degree, or degree unspecified) during each 
respective year. To increase consistency, programs were asked to classify glandular or coronal 
forms of hypospadias as first-degree hypospadias; subcoronal, distal penile, midshaft or proximal 
penile forms as second-degree hypospadias; and meatus openings on the scrotum or below 
(including penoscrotal or perineal hypospadias) as third-degree hypospadias. In addition, we 
reviewed information with each program’s leadership about their surveillance program, 
including the percentage of cases without available data on the degree of severity, the length of 
the ascertainment period after birth (e.g., inclusion of only diagnoses made before 1 year of age), 
whether the program used population-based (e.g., as opposed to hospital-based) case 
identification, and whether case diagnoses involved confirmation across multiple sources (e.g., 
diagnosis on more than one medical record). 
To better interpret the observed results, we also queried the director of each program for 
insights into the prevalence and trend results for their program.  We specifically asked: (1) How 
do you interpret your total prevalence of hypospadias being in the 1st / 2nd / 3rd/ 4th quartile? 
35 
 
(2) How do you interpret the increase / decrease observed in the joinpoint regression analysis of 
your program? These responses were used to interpret the results and organize the discussion of 
this paper.  
